파머징(Pharmerging) 시장 : 세계 산업 동향, 점유율, 규모, 성장, 기회 및 전망(2023-2028년)

Abstract

The global pharmerging market size reached US$ 1.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.2 Billion by 2028, exhibiting a growth rate (CAGR) of 12.2% during 2022-2028.

Pharmerging refers to a group of countries that hold low positioning in the pharmaceutical market but have a speedy growth. Some of the key pharmerging markets include China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, etc.

The increasing healthcare expenditures along with the rising number of private hospitals are currently propelling the global pharmerging market growth. Additionally, the high prevalence of numerous chronic diseases and growing consumer awareness towards early disease detection and treatment procedures are further augmenting the market growth. Moreover, the increasing geriatric population, who are more prone to serious medical conditions, such as dementia, hypertension, cardiac failure, etc., is also bolstering the demand for pharmaceuticals. Additionally, the introduction of government policies and reimbursement schemes across various countries for reducing the cost of treatment for chronic diseases is also propelling the market growth. Moreover, the growing number of insurance companies in the pharmerging countries offering numerous insurance policies to decrease the out-of-the-pocket expenditures is further augmenting the demand of pharmaceuticals in these countries. Apart from this, the rising investments in extensive R&D activities in the fields of biotechnology, immunology, oncology, etc., for the introduction of advanced treatments are also catalyzing the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmerging market report, along with forecasts at the global and country level from 2023-2028. Our report has categorized the market based on product, indication and distribution channel.

Breakup by Product:

Pharmaceuticals

Patented Prescription Drugs

Generic Prescription Drugs

OTC Drugs

Healthcare

Medical Devices

Clinical Diagnosis

Others

Breakup by Indication:

Lifestyle Diseases

Cancer and Autoimmune Diseases

Infectious Diseases

Others

Breakup by Distribution Channel:

Hospitals

Retail Pharmacies

Online Stores

Others

Breakup by Country:

Tier I

China

Tier II

India

Brazil

Russia

South Africa

Tier III

Argentina

Mexico

Poland

Ukraine

Turkey

Saudi Arabia

Egypt

Algeria

Nigeria

Thailand

Indonesia

Pakistan

Others

Competitive Landscape:

The competitive landscape of the industry has also been examined with some of the key players being Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Novartis AG and Teva Pharmaceutical Limited.

Key Questions Answered in This Report:

• How has the global pharmerging market performed so far and how will it perform in the coming years?
• What are the key regional markets?
• What is the impact of COVID-19 on the global pharmerging market?
• What is the breakup of the market based on the product?
• What is the breakup of the market based on the indication?
• What is the breakup of the market based on the distribution channel?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the market?
• What is the structure of the global pharmerging market and who are the key players?
• What is the degree of competition in the market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Pharmerging Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Pharmaceutical
  • 6.1.1 Market Trends
  • 6.1.2 Major Types
    • 6.1.2.1 Patented Prescription Drugs
    • 6.1.2.2 Generic Prescription Drugs
    • 6.1.2.3 OTC Drugs
  • 6.1.3 Market Forecast
• 6.2 Healthcare
  • 6.2.1 Market Trends
  • 6.2.2 Major Types
    • 6.2.2.1 Medical Devices
    • 6.2.2.2 Clinical Diagnosis
    • 6.2.2.3 Others
  • 6.2.3 Market Forecast

7 Market Breakup by Indication

• 7.1 Lifestyle Diseases
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Cancer and Autoimmune Diseases
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Infectious Diseases
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Stores
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Country

• 9.1 Tier I
  • 9.1.1 China
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
• 9.2 Tier II
  • 9.2.1 India
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Brazil
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 Russia
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Africa
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
• 9.3 Tier III
  • 9.3.1 Argentina
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 Mexico
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 Poland
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Ukraine
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Turkey
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Saudi Arabia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Egypt
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
  • 9.3.8 Algeria
    • 9.3.8.1 Market Trends
    • 9.3.8.2 Market Forecast
  • 9.3.9 Nigeria
    • 9.3.9.1 Market Trends
    • 9.3.9.2 Market Forecast
  • 9.3.10 Thailand
    • 9.3.10.1 Market Trends
    • 9.3.10.2 Market Forecast
  • 9.3.11 Indonesia
    • 9.3.11.1 Market Trends
    • 9.3.11.2 Market Forecast
  • 9.3.12 Pakistan
    • 9.3.12.1 Market Trends
    • 9.3.12.2 Market Forecast
  • 9.3.13 Others
    • 9.3.13.1 Market Trends
    • 9.3.13.2 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Sanofi S.A.
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Pfizer Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
    • 13.3.2.3 Financials
    • 13.3.2.4 SWOT Analysis
  • 13.3.3 AstraZeneca Plc.
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 GlaxoSmithKline Plc.
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 F. Hoffmann-La Roche AG (Roche AG)
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
    • 13.3.5.4 SWOT Analysis
  • 13.3.6 Eli Lilly and Company
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 Johnson & Johnson
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Abbott Laboratories
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Novartis AG
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Teva Pharmaceutical Limited
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financial
    • 13.3.10.4 SWOT Analysis